Reltecimod (TFA)

CAT: 0804-HY-P1698B-01Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-P1698B-01Size:5 mg
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Reltecimod (AB-103) TFA is a T-cell-specific surface glycoprotein CD28 (TP44) antagonist. Reltecimod TFA has beneficial effects against different bacterial infections, their exotoxins and endotoxins, and ionizing radiation. Reltecimod TFA modulates the inflammatory response by targeting and attenuating the critical CD28/B7-2 co-stimulatory pathway, without inhibiting it. Reltecimod TFA can be used to research necrotizing soft-tissue infections (NSTIs) [1].
Product Name Alternative
AB-103 (TFA)
UNSPSC
12352209
Target
Bacterial; CD28
Type
Peptides
Related Pathways
Anti-infection; Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Infection; Inflammation/Immunology; Cancer
Assay Protocol
https://www.medchemexpress.com/reltecimod-tfa.html
Purity
99.78
Solubility
DMSO : 100 mg/mL (ultrasonic) |H2O : < 0.1 mg/mL (ultrasonic; adjust pH to 3 with HCl)
Smiles
OC(C=C1)=CC=C1C[C@@H](C(N[C@@H](CC(O)=O)C(N[C@H](C)C(O)=O)=O)=O)NC([C@H](C)NC([C@H](C(C)C)NC([C@H](CC(C)C)NC([C@H](CCSC)NC([C@H]2N(CCC2)C([C@H](CO)NC([C@H](N)C)=O)=O)=O)=O)=O)=O)=O.OC(C(F)(F)F)=O.[x]
Molecular Formula
C46H72N10O15S.xC2HF3O2
Molecular Weight
1037.19 (free base)
References & Citations
[1]Edgar, R., Tarrio, M.L., Maislin, G. et al. Treatment with One Dose of Reltecimod is Superior to Two Doses in Mouse Models of Lethal Infection. Int J Pept Res Ther 26, 1669–1683 (2020) .
Shipping Conditions
Blue Ice
Storage Conditions
-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light)
Scientific Category
Peptides
Clinical Information
Phase 3

Popular Products